Sleep Aids Compared: OTC vs Prescription Options Guide
TL;DR
- Cognitive behavioral therapy for insomnia (CBT-I) is the recommended first-line treatment for chronic insomnia in adults, per AASM and ACP guidelines — not medication.
- OTC antihistamines (diphenhydramine, doxylamine) offer short-term relief but carry significant anticholinergic burden, especially in adults over 65.
- Melatonin has modest evidence for sleep-onset latency reduction and is best suited for circadian rhythm disorders.
- Prescription options — including dual orexin receptor antagonists (suvorexant, lemborexant), low-dose trazodone, and Z-drugs (zolpidem) — differ meaningfully in dependency risk, next-day impairment, and suitability for long-term use.
- No sleep aid replaces good sleep hygiene. All pharmacotherapy should be used at the lowest effective dose for the shortest duration necessary.
Understanding Insomnia and How Sleep Aids Work
Insomnia disorder — defined as difficulty initiating or maintaining sleep, or early-morning awakening with daytime impairment, occurring at least three nights per week for at least three months — affects an estimated 10–15% of the adult population chronically, with 30–35% experiencing short-term symptoms. The best sleep aid comparison starts not with which pill to take, but with understanding what drives the problem.
Sleep is regulated by two primary systems: the circadian process (Process C), governed by the suprachiasmatic nucleus and sensitive to light and melatonin, and the homeostatic sleep drive (Process S), which builds with waking hours through adenosine accumulation. Most pharmacological sleep aids act on one of several downstream targets:
- Histamine H1 receptors — blockade produces sedation (antihistamines)
- GABA-A receptors — positive allosteric modulation enhances inhibitory neurotransmission (benzodiazepines, Z-drugs)
- Orexin/hypocretin receptors — antagonism blocks wakefulness-promoting neuropeptides (dual orexin receptor antagonists, or DORAs)
- Melatonin MT1/MT2 receptors — agonism reinforces circadian signaling (melatonin, ramelteon)
- Serotonin 5-HT2A receptors — antagonism at low doses promotes slow-wave sleep (trazodone)
The American Academy of Sleep Medicine (AASM) and the American College of Physicians (ACP) agree that CBT-I should be offered as first-line therapy for chronic insomnia before any pharmacological intervention. CBT-I combines stimulus control, sleep restriction, cognitive restructuring, and sleep hygiene education — producing durable effects that persist after treatment ends, unlike most medications.
OTC Sleep Aids: Diphenhydramine, Doxylamine, and Melatonin
First-Generation Antihistamines
Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepGels) and doxylamine (Unisom SleepTabs) are the two first-generation H1-antihistamines marketed as OTC sleep aids. Both cross the blood-brain barrier readily and produce sedation by blocking central histamine receptors. Doxylamine is approximately 1.5 times more potent as a sedative than diphenhydramine at equivalent doses.
Key limitations of antihistamine sleep aids:
- Rapid tolerance — sedative effects diminish within 3–7 days of consecutive use, yet anticholinergic side effects persist.
- Anticholinergic burden — both agents block muscarinic receptors, causing dry mouth, urinary retention, constipation, blurred vision, and tachycardia. In older adults, cumulative anticholinergic exposure is associated with increased risk of cognitive impairment and falls.
- Next-day hangover — diphenhydramine has an elimination half-life of 4–8 hours (longer in elderly patients), and doxylamine 10–12 hours, frequently causing morning grogginess.
- No guideline endorsement — the AASM 2017 clinical practice guideline issued a statement that the evidence is insufficient to recommend diphenhydramine or doxylamine for the treatment of insomnia in adults.
The 2023 American Geriatrics Society (AGS) Beers Criteria explicitly list first-generation antihistamines as potentially inappropriate medications in older adults due to their strong anticholinergic properties and association with delirium, cognitive decline, and fracture risk.
Melatonin
Melatonin is a neurohormone produced by the pineal gland in response to darkness. Exogenous melatonin supplements — available OTC in the United States, though regulated as a prescription medication in much of Europe — act primarily on MT1 and MT2 receptors.
Evidence for melatonin in primary insomnia is modest. A 2013 meta-analysis (Ferracioli-Oda et al.) of 19 randomized controlled trials found melatonin reduced sleep-onset latency by approximately 7 minutes and increased total sleep time by about 8 minutes compared with placebo — statistically significant but of uncertain clinical relevance. Melatonin appears most effective for:
- Delayed sleep-wake phase disorder (circadian rhythm misalignment)
- Jet lag disorder
- Insomnia in adults over 55 (prolonged-release melatonin 2 mg is approved in the EU as Circadin for this indication)
A practical concern: melatonin supplements in the United States are regulated as dietary supplements, not drugs. A 2017 analysis published in the Journal of Clinical Sleep Medicine found that 71% of melatonin products tested had content that did not match the label, with actual melatonin content ranging from −83% to +478% of the stated dose. Some products also contained undeclared serotonin.
Prescription Sleep Medications: Evidence and Comparison
Trazodone
Trazodone (Desyrel) is a serotonin antagonist and reuptake inhibitor (SARI) originally approved as an antidepressant at doses of 150–400 mg/day. At low doses (25–100 mg), its dominant pharmacological action is 5-HT2A antagonism and H1 blockade, producing sedation without the anticholinergic effects of first-generation antihistamines.
Trazodone is the most commonly prescribed off-label medication for insomnia in the United States. Despite its widespread use, evidence supporting trazodone for insomnia is surprisingly thin. The AASM 2017 guideline issued a "VERSUS" (weakly against) recommendation for trazodone in insomnia treatment, citing limited and low-quality evidence. A small number of short-term RCTs suggest modest improvement in subjective sleep quality, but long-term data are lacking.
Advantages include minimal abuse potential, no scheduled-substance classification, and relative safety in overdose. Notable risks include orthostatic hypotension (especially in elderly patients), rare priapism (estimated 1 in 6,000–8,000 male patients), and QT prolongation at higher doses.
Z-Drugs: Zolpidem
Zolpidem (Ambien, Ambien CR) is a non-benzodiazepine hypnotic that selectively binds the alpha-1 subunit of the GABA-A receptor. It is FDA-approved for short-term treatment of insomnia characterized by difficulty with sleep initiation. The extended-release formulation additionally addresses sleep maintenance.
The AASM 2017 guideline provided a weak recommendation in favor of zolpidem for sleep-onset insomnia. However, several safety signals have tempered enthusiasm:
- In 2013, the FDA halved the recommended dose for women (from 10 mg to 5 mg for immediate-release) after pharmacokinetic data showed slower zolpidem clearance in women, leading to dangerously elevated next-morning blood levels.
- Complex sleep behaviors — including sleepwalking, sleep-driving, and sleep-eating — led to an FDA boxed warning in 2019 for all Z-drugs.
- Physical dependence can develop with nightly use beyond 2–4 weeks, and rebound insomnia upon discontinuation is well documented.
Dual Orexin Receptor Antagonists (DORAs)
Suvorexant (Belsomra, approved 2014) and lemborexant (Dayvigo, approved 2019) represent the newest class of prescription insomnia medications. Rather than broadly depressing CNS activity, DORAs selectively block orexin-A and orexin-B from binding their receptors (OX1R and OX2R), effectively silencing the wake-promoting orexin system while leaving other sleep architecture relatively intact.
Key distinctions between the two DORAs:
- Lemborexant has a shorter half-life (~17–19 hours vs ~12 hours for suvorexant), but its active metabolites contribute to the overall duration of effect. In head-to-head data from the SUNRISE-1 and SUNRISE-2 trials, lemborexant showed benefits for both sleep onset and sleep maintenance.
- Suvorexant was studied at doses up to 40 mg, but the FDA approved only 10 mg and 20 mg over concerns about next-day somnolence at higher doses.
Both DORAs received weak recommendations in favor from the AASM for sleep-onset and sleep-maintenance insomnia. Emerging longer-term safety data (up to 12 months) for lemborexant suggests no development of physical dependence or significant rebound insomnia — a meaningful advantage over Z-drugs and benzodiazepines.
Head-to-Head Comparison Table
| Feature | Diphenhydramine | Doxylamine | Melatonin | Trazodone | Zolpidem | Suvorexant | Lemborexant |
|---|---|---|---|---|---|---|---|
| Drug class | H1-antihistamine | H1-antihistamine | Neurohormone | SARI | Z-drug (GABA-A) | DORA | DORA |
| Availability | OTC | OTC | OTC (US) / Rx (EU) | Rx (off-label) | Rx (Schedule IV) | Rx (Schedule IV) | Rx (Schedule IV) |
| Onset | 30–60 min | 30–60 min | 30–60 min | 30–60 min | 15–30 min | 30 min | 30 min |
| Half-life | 4–8 h | 10–12 h | 1–2 h | 5–9 h | 2.5 h (IR) | ~12 h | ~17–19 h |
| Sleep onset | Modest | Modest | Modest | Weak evidence | Good evidence | Good evidence | Good evidence |
| Sleep maintenance | Poor | Poor | Minimal | Weak evidence | Moderate (CR form) | Good evidence | Good evidence |
| Tolerance risk | High (3–7 days) | High (3–7 days) | Low | Unclear | Moderate | Low | Low |
| Dependence/withdrawal | Low physical | Low physical | Negligible | Negligible | Moderate | Low | Low |
| Anticholinergic load | High | High | None | Very low | None | None | None |
| Beers list (≥65 y) | Yes — avoid | Yes — avoid | Not listed | Use with caution | Use with caution | Use with caution | Use with caution |
| AASM 2017 recommendation | Insufficient evidence | Insufficient evidence | N/A (not reviewed) | Weakly against | Weakly for | Weakly for | Weakly for |
Dosing Guidelines and Practical Use
The following table summarizes standard adult dosing. All doses represent the lowest effective starting dose; titration should be individualized.
| Medication | Starting dose | Maximum dose | Timing | Key administration notes |
|---|---|---|---|---|
| Diphenhydramine | 25 mg | 50 mg | 30 min before bed | Do not use >2 weeks; avoid in adults ≥65 |
| Doxylamine | 12.5–25 mg | 25 mg | 30 min before bed | Do not use >2 weeks; avoid in adults ≥65 |
| Melatonin (immediate-release) | 0.5 mg | 5 mg | 30–60 min before bed | Start low (0.5–1 mg); higher doses are not more effective |
| Melatonin (prolonged-release) | 2 mg | 2 mg | 1–2 h before bed | EU-approved (Circadin) for adults ≥55 |
| Trazodone | 25 mg | 100 mg (for insomnia) | 30 min before bed | Take with food to reduce orthostatic hypotension risk |
| Zolpidem IR | 5 mg (women) / 5 mg (men) | 10 mg | Immediately before bed | Ensure ≥7–8 h available for sleep; FDA recommends 5 mg start for all |
| Zolpidem ER | 6.25 mg | 12.5 mg | Immediately before bed | Do not crush or split extended-release tablets |
| Suvorexant | 10 mg | 20 mg | 30 min before bed | Take only if ≥7 h of sleep time available; avoid with strong CYP3A4 inhibitors |
| Lemborexant | 5 mg | 10 mg | Immediately before bed | Take only if ≥7 h of sleep time available; dose-reduce with moderate CYP3A4 inhibitors |
Practical tips for patients:
- Melatonin dosing is counterintuitive — physiological doses (0.5–1 mg) are often more effective than the 5–10 mg tablets commonly sold. Higher doses can cause daytime drowsiness, headache, and paradoxically disrupt circadian rhythm.
- Zolpidem must not be taken with or after a meal — food significantly delays absorption and onset, increasing the risk of next-morning impairment.
- DORAs should not be taken with alcohol — concurrent CNS depressant use amplifies somnolence and the risk of complex sleep behaviors.
Side Effects, Safety, and Monitoring
Anticholinergic Burden in Older Adults
The concept of cumulative anticholinergic burden is critical when evaluating sleep aids in patients over 65. Diphenhydramine and doxylamine each score 3 on the Anticholinergic Cognitive Burden (ACB) scale — the highest possible score — meaning they carry definite anticholinergic effects and are associated with cognitive impairment with chronic use.
A landmark 2015 prospective cohort study (Gray et al., JAMA Internal Medicine) of 3,434 participants aged ≥65 found that cumulative anticholinergic use equivalent to ≥3 years of daily diphenhydramine 25 mg was associated with a 54% increased risk of dementia compared with no use. While this observational association does not prove causation, it reinforces guideline recommendations to avoid these agents in elderly populations.
Dependency and Withdrawal Considerations
Zolpidem and other Z-drugs are Schedule IV controlled substances with recognized physical dependence liability. Withdrawal symptoms — including rebound insomnia, anxiety, tremor, and rarely seizures — can occur after abrupt discontinuation following prolonged use. Gradual tapering over 2–4 weeks is recommended.
DORAs (suvorexant and lemborexant) are also Schedule IV, but available data suggest lower physical dependence potential. In 12-month clinical trials, lemborexant showed no significant rebound insomnia upon discontinuation, and no withdrawal syndrome was observed in controlled settings.
Trazodone and melatonin are not controlled substances and carry minimal risk of physical dependence, though psychological reliance on any bedtime medication can develop.
Common and Serious Adverse Effects
| Adverse effect | Antihistamines | Melatonin | Trazodone | Zolpidem | DORAs |
|---|---|---|---|---|---|
| Daytime drowsiness | ++ | + | + | ++ | + |
| Dry mouth | ++ | — | + | — | — |
| Constipation | ++ | — | — | — | — |
| Dizziness / orthostatic hypotension | + | — | ++ | + | — |
| Complex sleep behaviors | — | — | — | +++ | + |
| Sleep paralysis / hypnagogic hallucinations | — | — | — | — | + |
| Falls (elderly) | ++ | — | ++ | ++ | + |
| Cognitive impairment (chronic) | +++ | — | — | + | Under study |
| Priapism | — | — | Rare | — | — |
Legend: — negligible; + mild/occasional; ++ moderate/common; +++ significant concern
Contraindications and Drug Interactions
Absolute contraindications:
- Diphenhydramine / doxylamine: severe hepatic impairment, concurrent MAO inhibitor use, narrow-angle glaucoma, urinary retention, known hypersensitivity
- Zolpidem: known history of complex sleep behaviors with prior Z-drug use (per FDA boxed warning, 2019)
- Suvorexant / lemborexant: narcolepsy (blocking orexin in an orexin-deficient condition is pharmacologically irrational), concurrent use with strong CYP3A4 inhibitors (suvorexant)
Key drug interactions:
| Sleep aid | Interacting drug/class | Clinical consequence |
|---|---|---|
| Diphenhydramine, doxylamine | Other anticholinergics (oxybutynin, tricyclics) | Additive anticholinergic toxicity |
| Diphenhydramine, doxylamine | CNS depressants (opioids, alcohol, benzodiazepines) | Excessive sedation, respiratory depression |
| Trazodone | MAO inhibitors | Serotonin syndrome risk |
| Trazodone | Strong CYP3A4 inhibitors (ketoconazole, ritonavir) | Increased trazodone levels |
| Zolpidem | CYP3A4 inhibitors (ketoconazole, clarithromycin) | Increased zolpidem exposure; dose reduction needed |
| Zolpidem | Rifampin (CYP3A4 inducer) | Decreased efficacy |
| Suvorexant | Strong CYP3A4 inhibitors | Contraindicated; dramatically increases suvorexant levels |
| Lemborexant | Strong CYP3A4 inhibitors | Avoid use; moderate inhibitors require dose reduction to 5 mg |
| Melatonin | Fluvoxamine (CYP1A2 inhibitor) | Markedly increased melatonin levels |
| Melatonin | Warfarin | Case reports of altered INR; monitor closely |
Special Populations
Older Adults (≥65 Years)
The approach to insomnia pharmacotherapy in older adults requires particular caution:
- Avoid first-generation antihistamines entirely (AGS Beers Criteria 2023).
- Zolpidem should be started at 5 mg (IR) or 6.25 mg (ER) with careful assessment for next-day impairment and fall risk.
- Trazodone carries meaningful orthostatic hypotension risk in this age group — if used, start at 12.5–25 mg with blood pressure monitoring.
- DORAs may represent a relatively safer pharmacological option for elderly patients with insomnia, as they do not increase fall risk to the same degree as GABAergic agents. However, sleep paralysis and hypnagogic hallucinations have been reported and may be distressing.
- CBT-I remains first-line and has demonstrated efficacy specifically in older adult populations.
Pregnancy and Lactation
- Diphenhydramine: generally considered compatible with pregnancy (no clear teratogenic signal in human data); present in breast milk.
- Doxylamine: combined with pyridoxine (Diclegis/Bonjesta) is FDA-approved for nausea of pregnancy, suggesting an acceptable safety profile; however, sedation in the nursing infant is a concern.
- Melatonin: insufficient human pregnancy data; ACOG does not endorse its use in pregnancy.
- Trazodone, zolpidem, suvorexant, lemborexant: limited pregnancy data; generally not recommended. Discuss risk-benefit with the prescribing physician.
Patients with Sleep Apnea
Untreated obstructive sleep apnea (OSA) is a relative or absolute contraindication for several sleep aids. GABAergic agents (zolpidem, benzodiazepines) can worsen upper-airway obstruction and reduce arousal responses. DORAs have been studied in patients with mild-to-moderate OSA and did not worsen the apnea-hypopnea index in clinical trials — a potential advantage for patients with comorbid insomnia and mild OSA, though data in severe OSA remain limited.
Red Flags — When to Seek Medical Attention
Seek urgent medical evaluation if you experience any of the following:
- Complex sleep behaviors — sleepwalking, sleep-driving, cooking, or making phone calls while not fully awake, especially after taking zolpidem or other sedative-hypnotics. Discontinue the medication and contact your prescriber immediately.
- Excessive daytime sleepiness causing impaired driving or workplace accidents
- Signs of allergic reaction — angioedema, anaphylaxis, or severe skin reactions
- Priapism (painful, prolonged erection lasting >4 hours) — a urological emergency associated with trazodone; seek emergency care immediately
- Worsening depression or suicidal thoughts — trazodone is an antidepressant, and changes in mood or emergence of suicidal ideation require prompt psychiatric evaluation
- Symptoms of serotonin syndrome — agitation, confusion, rapid heart rate, hyperthermia, muscle rigidity — particularly if combining trazodone with SSRIs, SNRIs, or other serotonergic agents
- Persistent insomnia lasting >3 months despite adequate sleep hygiene — this warrants formal evaluation for underlying conditions (sleep apnea, restless legs syndrome, psychiatric disorders, medical causes)
Frequently Asked Questions
Is melatonin safe to take every night?
Short-term use (up to 3 months) of melatonin at doses ≤5 mg appears to be well tolerated in adults, based on available clinical trial data. Long-term safety data beyond 6–12 months are limited, particularly for the unregulated OTC formulations available in the US. The prolonged-release 2 mg formulation (Circadin) has been studied for up to 6 months in adults ≥55 in Europe. If you need a sleep aid nightly for more than a few weeks, consult your physician — the underlying insomnia likely warrants formal evaluation.
What is the difference between doxylamine and diphenhydramine for sleep?
Both are first-generation antihistamines with sedative properties. Doxylamine is generally considered more potent as a sedative and has a longer half-life (10–12 h vs 4–8 h), which may mean more pronounced next-morning grogginess. Neither is recommended for use beyond two weeks, and both carry equivalent anticholinergic risks. For most patients, neither is an optimal long-term choice.
Is trazodone addictive?
Trazodone is not a controlled substance and does not produce the physical dependence or euphoria associated with benzodiazepines or Z-drugs. However, patients who use trazodone nightly for months may experience difficulty sleeping without it — a phenomenon that reflects psychological reliance and possible mild rebound insomnia rather than true pharmacological dependence. Gradual dose reduction is still advisable when discontinuing.
How do suvorexant and lemborexant compare?
Both are dual orexin receptor antagonists (DORAs) with similar mechanisms and clinical efficacy. Lemborexant was approved more recently and has clinical trial data (SUNRISE program) showing benefits for both sleep onset and sleep maintenance, including in elderly patients. It has a longer terminal half-life but appears to have comparable next-day function profiles. Suvorexant has a longer post-marketing track record. Choice between them is often guided by formulary availability, insurance coverage, and individual response.
Can I take a sleep aid with alcohol?
No. Combining any sleep medication — OTC or prescription — with alcohol increases the risk of excessive sedation, respiratory depression, falls, and complex sleep behaviors. This is especially dangerous with zolpidem and other GABAergic agents. Alcohol itself disrupts sleep architecture (suppressing REM sleep and increasing nighttime awakenings) and will counteract the benefits of any sleep aid.
Should I try CBT-I before medication?
Yes, whenever possible. Both the AASM and ACP recommend CBT-I as first-line treatment for chronic insomnia in adults. CBT-I has been shown to produce improvements in sleep quality that are comparable to medication in the short term and superior to medication in the long term, because the skills learned in therapy persist after treatment ends. CBT-I is available through trained therapists, structured digital programs (some FDA-cleared), and increasingly through telehealth platforms.
Are OTC sleep aids safer than prescription ones?
Not necessarily. OTC status reflects regulatory history and market classification, not superior safety. First-generation antihistamines carry significant anticholinergic risks that many prescription options do not. The assumption that "over-the-counter means safe for everyone" is particularly dangerous for older adults and those taking multiple medications.
How long can I safely take zolpidem?
Zolpidem is FDA-approved for short-term treatment, typically defined as 2–4 weeks. In clinical practice, some patients use it intermittently or for longer periods under close supervision. The key concern with extended use is tolerance, dependence, and the risk of complex sleep behaviors, which may increase with duration of use. If you have been taking zolpidem nightly for more than a month, discuss a tapering plan with your prescriber.
References
-
Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307–349. PMID: 27998379
-
Qaseem A, Kansagara D, Forciea MA, et al. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;165(2):125–133. PMID: 27136449
-
Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–407. PMID: 25621434
-
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8(5):e63773. PMID: 23691095
-
Erland LA, Saxena PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med. 2017;13(2):275–281. PMID: 27855744
-
FDA. FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines. Drug Safety Communication. 2019. fda.gov
-
FDA. FDA requires lower recommended doses for certain sleep drugs containing zolpidem. Drug Safety Communication. 2013. fda.gov
-
Rosenberg R, Murphy P, Zammit G, et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2(12):e1918254. PMID: 31880796
-
Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016;79(2):136–148. PMID: 25526970
-
American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. PMID: 37139824
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with over 15 years of experience in drug information, medication safety, and patient education. He has practiced in hospital, community, and consulting pharmacy settings, with particular expertise in psychopharmacology and geriatric medicine. Dr. Ozarchuk writes for PillsCard.com to help patients and caregivers make informed, evidence-based decisions about their medications.
Medical Disclaimer
This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The content provided reflects general pharmacological and clinical information current at the time of writing and should not replace individualized guidance from a qualified healthcare professional. Always consult your physician, pharmacist, or other licensed healthcare provider before starting, changing, or discontinuing any medication. Do not disregard professional medical advice or delay seeking it based on information in this article. If you are experiencing a medical emergency, call your local emergency services immediately.